Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06659224Completed

The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma

Role: lead

NCT06978595Completed

Primary Colorectal Signet Ring Cell Carcinoma and the Risk of Multiple Primary Gastrointestinal Malignancies

Role: lead

NCT06620926Completed

Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma

Role: lead

NCT06662734Completed

Infantile Versus Adult-type Fibrosarcoma and the Risk of Multiple Primary Malignancies

Role: lead

NCT06619535Completed

Sepsis As a Cause of Death Among Elderly Cancer Patients

Role: lead

All 5 trials loaded